Viewing Study NCT05559450



Ignite Creation Date: 2024-05-06 @ 6:07 PM
Last Modification Date: 2024-10-26 @ 2:42 PM
Study NCT ID: NCT05559450
Status: RECRUITING
Last Update Posted: 2022-09-29
First Post: 2022-09-26

Brief Title: Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL
Sponsor: The First Affiliated Hospital of Soochow University
Organization: The First Affiliated Hospital of Soochow University

Study Overview

Official Title: A Multicenter Prospective Randomized Clinical Trial of Blinatumomab As a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation in High Risk Precursor B-cell Acute Lymphoblastic Leukemia
Status: RECRUITING
Status Verified Date: 2021-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To explore the efficacy and safty of Blinatumomab as a bridge to Allogeneic Hematopoietic Stem Cell Transplantation in High Risk Precursor B-cell Acute Lymphoblastic Leukemia
Detailed Description: High Risk Precursor B-cell Acute Lymphoblastic Leukemia is a kind of leukemia with poor prognosis Here we want to explore the efficacy and safty of Blinatumomab as a bridge to Allogeneic Hematopoietic Stem Cell Transplantation in High Risk Precursor B-cell Acute Lymphoblastic Leukemia

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: None